Efficacy Study of LIQUICURE™ to Treat Toe Nail Fungus

NCT ID: NCT00960089

Last Updated: 2016-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a major clinical need for an inexpensive topically-applied product that can inhibit the growth of the dermatophytes that cause nail fungus. Chesson Labs has developed LIQUICURE with a longer drying/curing time that will allow better nail penetration or adsorption. Though the product may have inherent antimicrobial activity, the product does not contain a drug or antimicrobial agent.

Consistent use of LIQUICURE as described will clear fungal nail infection. Clearing of nail fungal infection is defined by negative dermatophyte culture and visual improvement in nail characteristics within six months, with few, if any product-related adverse events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Onychomycosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LIQUICURE

Medical Device

Group Type EXPERIMENTAL

LIQUICURE

Intervention Type DEVICE

Topical treatment, 1 time/day, 5 days/week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LIQUICURE

Topical treatment, 1 time/day, 5 days/week

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Nail fungal infection of at least one great toe \[per visual assessment, positive KOH preparation, and positive dermatophyte culture\]
* Subjects who have target toenail showing 20-65% involvement as judged by the clinical investigator
* 2 mm of clear nail proximally on great toenail / no lunula involvement
* Subject must be physically able to reach toes to clean them and apply product
* Subject is willing to discontinue use of other nail fungus treatment products and nail cosmetic products for duration of this study
* Subject is willing and available to return for study follow up
* Ability of the subject or legal representative to understand and provide signed consent for participating in the study
* Negative urine pregnancy test for women of child bearing age
* Females must be post menopausal or must agree to use approved contraceptives (actions, devices or medications to prevent or reduce the likelihood of pregnancy) throughout the study (Note: abstinence is NOT an accepted form of contraception)

Exclusion Criteria

* Known hypersensitivity or allergy to the product materials
* Negative KOH preparation or dermatophyte culture
* Thickness of nail greater than 3 mm
* Enrollment in another investigational drug or product protocol that would interfere with this study
* Continuation or use of other topical or pharmaceutical treatments for the condition; a wash-out period of at least four weeks after discontinuation of a topical product or 180 days after discontinuation of an oral product for treatment of nail fungus is required
* Chronic disease, including: diabetes, psoriasis, immune deficiency, severe foot injury, chronic vascular disease or any other condition that would decrease circulation to the extremities at the discretion of the investigator Pregnant or nursing females
* Investigators, Chesson personnel, or Chesson Scientific Advisory Board members or their immediate family
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chesson Laboratory Associates, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Beth Goldstein, MD

Role: PRINCIPAL_INVESTIGATOR

Central Dermatology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Triangle Medical Research Associates

Cary, North Carolina, United States

Site Status

Central Dermatology Center

Chapel Hill, North Carolina, United States

Site Status

Wake Research Associates

Raleigh, North Carolina, United States

Site Status

Crescent Medical Research

Salisbury, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Chesson Labs CT001-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lasers in Onychomycosis
NCT05415852 UNKNOWN NA